Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Conditions

• Locally Advanced Lung Non-Small Cell Carcinoma
• Locally Recurrent Lung Non-Small Cell Carcinoma
• Stage II Lung Cancer AJCC v8
• Stage III Lung Cancer AJCC v8
• Unresectable Lung Non-Small Cell Carcinoma

Interventions

• RADIATION: Accelerated Hypofractionated Radiation Therapy
• PROCEDURE: Biospecimen Collection
• PROCEDURE: Computed Tomography
• BIOLOGICAL: Durvalumab
• PROCEDURE: Magnetic Resonance Imaging of the Brain with and without Contrast
• BIOLOGICAL: Monalizumab
• BIOLOGICAL: Oleclumab
• RADIATION: Radiation Therapy

Sponsor

National Cancer Institute (NCI)

Collaborators

• [object Object]